David Patsouris

Passionné par la recherche biomédicale et les sports d’endurance. Ici pour ma culture. Mes tweets ne représentent que mon opinion.

[Insee @InseeFr]

#Démographie | D’ici 2070, le nombre d’habitants de moins de 45 ans baisserait de 8,9 millions, tandis que celui des personnes âgées de 45 à 64 ans serait quasi stable et que celui de 65 ans ou plus augmenterait de 5,8 millions.
👉https://t.co/TKT6ix1c6i

[Nicolas Chéron @NCheron_bourse]

En France, depuis 50 ans, le coût d'un employé augmente plus vite que son salaire net.

Je n'ai pas les mots.

[David Patsouris @_David_Pat_]

Les patients inclus dans les études sur des agonistes aux GLP1 qui pensent être dans le bras placebo vont s’en procurer d’eux même. Toute études avec un bras placebo sur les a de glp1 semble désuète.

[Jen Can NuSH @JCanNuSH]

Double digit percent of placebo patients cheated and went on GLP-1s! Yikes!

[C dans l'air @Cdanslair]

⬛ Pr Steven Le Gouill, médecin hématologue, directeur des hôpitaux de l'Institut Curie, vice-président d'Unicancer, est l'invité de @AureCasse dans #cdanslair.

Rendez-vous à 17.25 sur France 5 !

[David Patsouris @_David_Pat_]

150 traitements potentiels en cours de développement… c’est une révolution qui est en cours.

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

In the past 5 years alone, the number of clinical trials studying #obesity medications has increased nearly five-fold and more than 150 potential drugs are currently in the development pipeline https://t.co/IFPyEU8bKn
#weightloss #GLP-1 receptor agonists

[François Valentin @Valen10Francois]

Keep those numbers in mind when they start saying that we need to tax the rich...

[David Patsouris @_David_Pat_]

@Hugo_Baup La fameuse « bigorexie »? Je trouve que la pratique en compétition rend l’auto évaluation difficile car ça donne envie de faire mieux et progresser.

[David Patsouris @_David_Pat_]

Évolution des aGLP1. Les traitements oraux sont approuvés aux usa. En développement: des traitements injectables à longue durée d’action (une fois pas mois).

[Michael Weintraub, MD @MWeintraubMD]

Previewing some data that will report at next week's American Diabetes Association Scientific Sessions:

Pfizer's monthly GLP-1 berobenatide phase 2b trial in adults with obesity. Both those with type 2 diabetes and without type 2 diabetes.

Top line results report 12.3% weight loss at week 28.

Looking forward to VESPER-3 presentation June 6th

https://t.co/741edHlVcR

[Dr. Alex Tatem @DrAlexTatem]

🚨 LILLY WANTS TO KILL AFFORDABLE RETATRUTIDE.

The whole story, and why you should care 👇

Right now Eli Lilly is in court fighting to reclassify retatrutide as a "biologic." If they win, the drug gets locked behind a 12-year wall and compounded reta is gone for good.

And the whole thing hinges on TWO amino acids.

Reta is a 39-amino-acid peptide. Anything over 40 gets classified as a biologic instead of a regular drug. Lilly wants 2 extra tacked-on amino acids counted so it crosses that line.

Why fight this hard over what's basically a rounding error?

🔒 Biologic = 12 years of market exclusivity vs 5 for a normal drug
🔒 Biologic = permanently ineligible for compounding (no compounded reta, ever)
🔒 Biologic = years longer before Medicare can negotiate the price, while taxpayers foot the bill

There's also a quieter motive: reta is stronger than tirzepatide (Mounjaro/Zepbound). Locking it up protects Lilly's blockbuster from getting cannibalized by its own better drug.

Two amino acids should not decide whether millions can afford treatment.

📣 Tell your Reps and Senators to pay attention to this case. Find yours: https://t.co/izrpOlOcCw

@LillyPad @a4pcrx @US_FDA @hubermanlab @thegarybrecka

[David Patsouris @_David_Pat_]

@moniaceleste @barriere_dr @Kevin_Boulat https://t.co/kMd2N7bgND Bonjour @moniaceleste sais tu faire la synthèse d’articles non publiés sur lel comme celui là par ex?

[BioSpace @biospace]

The American Diabetes Association’s annual congress will feature a superstar lineup. But several scrappy biotechs will also present obesity candidates with the potential to match—if not outperform—their deep-pocketed competitors.

https://t.co/x1P1r29AXc

[Eric Topol @EricTopol]

There hasn't previously been a treatment vs pancreatic cancer this successful. Striking improved (a > doubling) survival results @NEJM and @ASCO today with daraxonrasib, which also became available via an FDA approved early access program and began shipping to physicians this week @RevMedicines
https://t.co/e04jqJMPw0

[Eric K. Singhi, MD @lungoncdoc]

7yr CROWN update of 1L lorlatinib

55% progression-free at 7 YEARS.
Median PFS STILL not reached.

In metastatic solid tumors, this is essentially unheard of. Let that sink in.

And hopefully, one day, this becomes the standard (or even better) for ALL metastatic cancers.#ASCO26

[L'Équipe @lequipe]

Héroïques au bout d'un match 7 épique, les Texans ont arraché leur qualification en finale NBA où ils retrouveront les New York Knicks. Victor Wembanyama aura été un des grands artisans de la victoire des Texans, particulièrement adroits à trois points samedi soir.
➡️ https://t.co/gwG6kaxi5q

[San Antonio Spurs @spurs]

FINALS BOUND 🎉

@HEB | @Ledger

[David Patsouris @_David_Pat_]

@hairy_addict @Fraslin https://t.co/EyVMU3mDw0 étude meta indepedante

[David Patsouris @_David_Pat_]

@hairy_addict @Fraslin Il y a pléthore de références https://t.co/G6pht7rBUN

[Scott Isaacs @scottisaacsmd]

Mean percent weight loss change was 21.6% with #tirzepatide vs. 15.4% with #semaglutide in SURMOUNT-5.

https://t.co/8qpOL9Ze25

[David Patsouris @_David_Pat_]

https://t.co/JuB8bdoj7F

[David Patsouris @_David_Pat_]

Tirzepatide >>> other aGLP1

[Scott Isaacs @scottisaacsmd]

SURPASS‑EARLY evaluated starting tirzepatide early in type 2 diabetes vs. conventional step-therapy. In adults with early T2D on metformin, tirzepatide produced larger 2‑year reductions in HbA1c, weight, and waist circumference than intensified conventional care, and more participants achieved normoglycemia. Although the open‑label design can introduce reporting bias and patients with very high baseline HbA1c (>9.5%) were excluded, the findings support considering GLP medications earlier to establish better and potentially more durable glycemic control than stepwise conventional care.
https://t.co/RnDtoMyzWg

[David Patsouris @_David_Pat_]

@AMistl57 @Fraslin https://t.co/JuB8bdoj7F

[David Patsouris @_David_Pat_]

@hairy_addict @Fraslin https://t.co/JuB8bdoj7F